Systems-biology dissection of mechanisms and chemical basis of herbal formula in treating chronic myocardial ischemia.
暂无分享,去创建一个
Jianxin Chen | Wei Wang | Peng Li | Shuzhen Guo | Kuo Gao | Wuxia Zhang | Bangze Fu | Wenjing Chuo | Junyao Wang | Peng Li
[1] Jianxin Chen,et al. Chinese Herbal Medicine in the Treatment of Chronic Heart Failure: Three-Stage Study Protocol for a Randomized Controlled Trial , 2015, Evidence-based complementary and alternative medicine : eCAM.
[2] Peng Li,et al. Insights from systems pharmacology into cardiovascular drug discovery and therapy , 2014, BMC Systems Biology.
[3] Peng Yang,et al. Microbial community pattern detection in human body habitats via ensemble clustering framework , 2014, BMC Systems Biology.
[4] Huajun Chen,et al. Modern bioinformatics meets traditional Chinese medicine , 2014, Briefings Bioinform..
[5] Johannes M. I. H. Gho,et al. Myocardial Infarction and Functional Outcome Assessment in Pigs , 2014, Journal of visualized experiments : JoVE.
[6] Wei Wang,et al. Time-Course of the Effects of QSYQ in Promoting Heart Function in Ameroid Constrictor-Induced Myocardial Ischemia Pigs , 2014, Evidence-based complementary and alternative medicine : eCAM.
[7] Mark A Sussman,et al. Fibronectin contributes to pathological cardiac hypertrophy but not physiological growth , 2013, Basic Research in Cardiology.
[8] P. Clemons,et al. Target identification and mechanism of action in chemical biology and drug discovery. , 2013, Nature chemical biology.
[9] Jane A. Linderbaum,et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.
[10] J. Molkentin,et al. Signaling effectors underlying pathologic growth and remodeling of the heart. , 2013, The Journal of clinical investigation.
[11] R. Hajjar,et al. Altered sarcoplasmic reticulum calcium cycling—targets for heart failure therapy , 2012, Nature Reviews Cardiology.
[12] Wei Wang,et al. Cardioprotective Effects of Qishenyiqi Mediated by Angiotensin II Type 1 Receptor Blockade and Enhancing Angiotensin-Converting Enzyme 2 , 2012, Evidence-based complementary and alternative medicine : eCAM.
[13] J. Loscalzo,et al. The Emerging Paradigm of Network Medicine in the Study of Human Disease , 2012, Circulation research.
[14] Arthur N Westover,et al. Do prescription stimulants increase the risk of adverse cardiovascular events?: A systematic review , 2012, BMC Cardiovascular Disorders.
[15] Wei Wang,et al. Drug Target Prediction Based on the Herbs Components: The Study on the Multitargets Pharmacological Mechanism of Qishenkeli Acting on the Coronary Heart Disease , 2012, Evidence-based complementary and alternative medicine : eCAM.
[16] W. Chan,et al. New insights into mechanisms of action of carvedilol treatment in chronic heart failure patients--a matter of time for contractility. , 2012, Journal of cardiac failure.
[17] E. Rodríguez-Sánchez,et al. Ambulatory arterial stiffness indices and target organ damage in hypertension , 2012, BMC Cardiovascular Disorders.
[18] F. Cheung. TCM: Made in China , 2011, Nature.
[19] V. Gewin. Turning point: Jonathan Cirtain , 2011, Nature.
[20] Yang Song,et al. Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery , 2011, Nucleic Acids Res..
[21] Patrick M. McLendon,et al. Desmin-related cardiomyopathy: an unfolding story. , 2011, American journal of physiology. Heart and circulatory physiology.
[22] David S. Wishart,et al. DrugBank 3.0: a comprehensive resource for ‘Omics’ research on drugs , 2010, Nucleic Acids Res..
[23] M. Galsky,et al. Docetaxel-based combination therapy for castration-resistant prostate cancer. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[24] J. Tamargo,et al. New investigational drugs for the management of acute heart failure syndromes. , 2010, Current medicinal chemistry.
[25] Adriano Lazzarin,et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial , 2009, The Lancet.
[26] N. Turner,et al. Cardiac fibroblasts: at the heart of myocardial remodeling. , 2009, Pharmacology & therapeutics.
[27] M. Hanefeld,et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial , 2009, The Lancet.
[28] Xiaohua Ma,et al. Mechanisms of drug combinations: interaction and network perspectives , 2009, Nature Reviews Drug Discovery.
[29] De-Xin Kong,et al. Where is the hope for drug discovery? Let history tell the future. , 2009, Drug discovery today.
[30] A. Hoes,et al. Clinical epidemiology of heart failure , 2007, Heart.
[31] L. Opie,et al. Metabolic mechanisms in heart failure. , 2007, Circulation.
[32] J. Qiu. News feature: 'Back to the future' for Chinese herbal medicines , 2007, Nature Reviews Drug Discovery.
[33] Michael J. Keiser,et al. Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.
[34] H. Krum,et al. Drug discovery for heart failure: a new era or the end of the pipeline? , 2007, Nature Reviews Drug Discovery.
[35] Paul A Clemons,et al. The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.
[36] J. Molkentin,et al. Regulation of cardiac hypertrophy by intracellular signalling pathways , 2006, Nature Reviews Molecular Cell Biology.
[37] H. Kitano. Cancer as a robust system: implications for anticancer therapy , 2004, Nature Reviews Cancer.
[38] D. Coates. The angiotensin converting enzyme (ACE). , 2003, The international journal of biochemistry & cell biology.
[39] AlanMaisel. B-Type Natriuretic Peptide Levels: Diagnostic and Prognostic in Congestive Heart Failure , 2002 .
[40] A. Maisel,et al. B-type natriuretic peptide levels: diagnostic and prognostic in congestive heart failure: what's next? , 2002, Circulation.
[41] J. Huss,et al. PPAR signaling in the control of cardiac energy metabolism. , 2000, Trends in cardiovascular medicine.
[42] J. Schaper,et al. The role of the cytoskeleton in heart failure. , 2000, Cardiovascular research.
[43] M. K. Magnússon,et al. Fibronectin: structure, assembly, and cardiovascular implications. , 1998, Arteriosclerosis, thrombosis, and vascular biology.
[44] C. Wayman,et al. Capacitative Ca2+ entry and the regulation of smooth muscle tone. , 1998, Trends in pharmacological sciences.
[45] Robert H. Anderson,et al. Anatomy of the pig heart: comparisons with normal human cardiac structure , 1998, Journal of anatomy.
[46] D Hare,et al. The Orange Book: the Food and Drug Administration's advice on therapeutic equivalence. , 1990, American pharmacy.
[47] W. Yao,et al. A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of qili qiangxin capsules in patients with chronic heart failure. , 2013, Journal of the American College of Cardiology.
[48] Maarten L. Simoons,et al. The third universal definition of myocardial infarction , 2013 .
[49] A. Papavassiliou,et al. The role of inflammation in heart failure: new therapeutic approaches. , 2011, Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese.
[50] Brad T. Sherman,et al. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.
[51] C. Long,et al. The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. , 2005, Annual review of pharmacology and toxicology.
[52] G. Lamas,et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients wi , 2004, Journal of the American College of Cardiology.